SrasV1, PascalFrancis, Checkpoint, bibRecord, 000299

A single amino acid substitution in the Sl and S2 Spike protein domains determines the neutralization escape phenotype of SARS-CoV

Identifieur interne : 000299 ( PascalFrancis/Checkpoint ); précédent : 000298; suivant : 000300

A single amino acid substitution in the Sl and S2 Spike protein domains determines the neutralization escape phenotype of SARS-CoV

Auteurs : Yu-Ya Mitsuki [Japon] ; Kazuo Ohnishi [Japon] ; Hirotaka Takagi [Japon] ; Masamichi Oshima [Japon] ; Takuya Yamamoto [Japon] ; Fuminori Mizukoshi [Japon] ; Kazutaka Terahara [Japon] ; Kazuo Kobayashi [Japon] ; Naoki Yamamoto [Japon] ; Shoji Yamaoka [Japon] ; Yasuko Tsunetsugu-Yokota [Japon]

Source :

Microbes and infection [ 1286-4579 ] ; 2008.

RBID : Pascal:08-0451539

Descripteurs français

Pascal (Inist)
- Virus syndrome respiratoire aigu sévère, Protéine, Neutralisation, Phénotype, Mutation, Anticorps neutralisant, Immunothérapie.

English descriptors

KwdEn :
- Immunotherapy, Mutation, Neutralization, Neutralizing antibody, Phenotype, Protein, Severe acute respiratory syndrome virus.

Abstract

In response to SARS-CoV infection, neutralizing antibodies are generated against the Spike (S) protein. Determination of the active regions that allow viral escape from neutralization would enable the use of these antibodies for future passive immunotherapy. We immunized mice with UV-inactivated SARS-CoV to generate three anti-S monoclonal antibodies, and established several neutralization escape mutants with S protein. We identified several amino acid substitutions, including Y442F and V601G in the S1 domain and D757N and A834V in the S2 region. In the presence of each neutralizing antibody, double mutants with substitutions in both domains exhibited a greater growth advantage than those with only one substitution. Importantly, combining two monoclonal antibodies that target different epitopes effected almost complete suppression of wild type virus replication. Thus, for effective passive immunotherapy, it is important to use neutralizing antibodies that recognize both the S1 and S2 regions.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000251
to stream PascalFrancis, to step Curation: 000737

Links to Exploration step

Pascal:08-0451539

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A single amino acid substitution in the Sl and S2 Spike protein domains determines the neutralization escape phenotype of SARS-CoV</title>
<author><name sortKey="Mitsuki, Yu Ya" sort="Mitsuki, Yu Ya" uniqKey="Mitsuki Y" first="Yu-Ya" last="Mitsuki">Yu-Ya Mitsuki</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Immunology, National Institute of Infectious Diseases, Toyama 1-23-1</s1>
<s2>Shinjuku-ku, Tokyo 162-8640</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Molecular Virology, Graduate School of Medicine, Tokyo Medical and Dental University</s1>
<s2>Tokyo 113-8519</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ohnishi, Kazuo" sort="Ohnishi, Kazuo" uniqKey="Ohnishi K" first="Kazuo" last="Ohnishi">Kazuo Ohnishi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Immunology, National Institute of Infectious Diseases, Toyama 1-23-1</s1>
<s2>Shinjuku-ku, Tokyo 162-8640</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Takagi, Hirotaka" sort="Takagi, Hirotaka" uniqKey="Takagi H" first="Hirotaka" last="Takagi">Hirotaka Takagi</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Division of Biosafety Control and Research, National Institute of Infectious Diseases</s1>
<s2>Shinjuku-ku, Tokyo 162-8640</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Oshima, Masamichi" sort="Oshima, Masamichi" uniqKey="Oshima M" first="Masamichi" last="Oshima">Masamichi Oshima</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Immunology, National Institute of Infectious Diseases, Toyama 1-23-1</s1>
<s2>Shinjuku-ku, Tokyo 162-8640</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yamamoto, Takuya" sort="Yamamoto, Takuya" uniqKey="Yamamoto T" first="Takuya" last="Yamamoto">Takuya Yamamoto</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Immunology, National Institute of Infectious Diseases, Toyama 1-23-1</s1>
<s2>Shinjuku-ku, Tokyo 162-8640</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mizukoshi, Fuminori" sort="Mizukoshi, Fuminori" uniqKey="Mizukoshi F" first="Fuminori" last="Mizukoshi">Fuminori Mizukoshi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Immunology, National Institute of Infectious Diseases, Toyama 1-23-1</s1>
<s2>Shinjuku-ku, Tokyo 162-8640</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Terahara, Kazutaka" sort="Terahara, Kazutaka" uniqKey="Terahara K" first="Kazutaka" last="Terahara">Kazutaka Terahara</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Immunology, National Institute of Infectious Diseases, Toyama 1-23-1</s1>
<s2>Shinjuku-ku, Tokyo 162-8640</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kobayashi, Kazuo" sort="Kobayashi, Kazuo" uniqKey="Kobayashi K" first="Kazuo" last="Kobayashi">Kazuo Kobayashi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Immunology, National Institute of Infectious Diseases, Toyama 1-23-1</s1>
<s2>Shinjuku-ku, Tokyo 162-8640</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yamamoto, Naoki" sort="Yamamoto, Naoki" uniqKey="Yamamoto N" first="Naoki" last="Yamamoto">Naoki Yamamoto</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Molecular Virology, Graduate School of Medicine, Tokyo Medical and Dental University</s1>
<s2>Tokyo 113-8519</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>AIDS Research Center, National Institute of Infectious Diseases</s1>
<s2>Shinjuku-ku, Tokyo 162-8640</s2>
<s3>JPN</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yamaoka, Shoji" sort="Yamaoka, Shoji" uniqKey="Yamaoka S" first="Shoji" last="Yamaoka">Shoji Yamaoka</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Molecular Virology, Graduate School of Medicine, Tokyo Medical and Dental University</s1>
<s2>Tokyo 113-8519</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tsunetsugu Yokota, Yasuko" sort="Tsunetsugu Yokota, Yasuko" uniqKey="Tsunetsugu Yokota Y" first="Yasuko" last="Tsunetsugu-Yokota">Yasuko Tsunetsugu-Yokota</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Immunology, National Institute of Infectious Diseases, Toyama 1-23-1</s1>
<s2>Shinjuku-ku, Tokyo 162-8640</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0451539</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0451539 INIST</idno>
<idno type="RBID">Pascal:08-0451539</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000251</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000737</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000299</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000299</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A single amino acid substitution in the Sl and S2 Spike protein domains determines the neutralization escape phenotype of SARS-CoV</title>
<author><name sortKey="Mitsuki, Yu Ya" sort="Mitsuki, Yu Ya" uniqKey="Mitsuki Y" first="Yu-Ya" last="Mitsuki">Yu-Ya Mitsuki</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Immunology, National Institute of Infectious Diseases, Toyama 1-23-1</s1>
<s2>Shinjuku-ku, Tokyo 162-8640</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Molecular Virology, Graduate School of Medicine, Tokyo Medical and Dental University</s1>
<s2>Tokyo 113-8519</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ohnishi, Kazuo" sort="Ohnishi, Kazuo" uniqKey="Ohnishi K" first="Kazuo" last="Ohnishi">Kazuo Ohnishi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Immunology, National Institute of Infectious Diseases, Toyama 1-23-1</s1>
<s2>Shinjuku-ku, Tokyo 162-8640</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Takagi, Hirotaka" sort="Takagi, Hirotaka" uniqKey="Takagi H" first="Hirotaka" last="Takagi">Hirotaka Takagi</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Division of Biosafety Control and Research, National Institute of Infectious Diseases</s1>
<s2>Shinjuku-ku, Tokyo 162-8640</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Oshima, Masamichi" sort="Oshima, Masamichi" uniqKey="Oshima M" first="Masamichi" last="Oshima">Masamichi Oshima</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Immunology, National Institute of Infectious Diseases, Toyama 1-23-1</s1>
<s2>Shinjuku-ku, Tokyo 162-8640</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yamamoto, Takuya" sort="Yamamoto, Takuya" uniqKey="Yamamoto T" first="Takuya" last="Yamamoto">Takuya Yamamoto</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Immunology, National Institute of Infectious Diseases, Toyama 1-23-1</s1>
<s2>Shinjuku-ku, Tokyo 162-8640</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mizukoshi, Fuminori" sort="Mizukoshi, Fuminori" uniqKey="Mizukoshi F" first="Fuminori" last="Mizukoshi">Fuminori Mizukoshi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Immunology, National Institute of Infectious Diseases, Toyama 1-23-1</s1>
<s2>Shinjuku-ku, Tokyo 162-8640</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Terahara, Kazutaka" sort="Terahara, Kazutaka" uniqKey="Terahara K" first="Kazutaka" last="Terahara">Kazutaka Terahara</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Immunology, National Institute of Infectious Diseases, Toyama 1-23-1</s1>
<s2>Shinjuku-ku, Tokyo 162-8640</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kobayashi, Kazuo" sort="Kobayashi, Kazuo" uniqKey="Kobayashi K" first="Kazuo" last="Kobayashi">Kazuo Kobayashi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Immunology, National Institute of Infectious Diseases, Toyama 1-23-1</s1>
<s2>Shinjuku-ku, Tokyo 162-8640</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yamamoto, Naoki" sort="Yamamoto, Naoki" uniqKey="Yamamoto N" first="Naoki" last="Yamamoto">Naoki Yamamoto</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Molecular Virology, Graduate School of Medicine, Tokyo Medical and Dental University</s1>
<s2>Tokyo 113-8519</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>AIDS Research Center, National Institute of Infectious Diseases</s1>
<s2>Shinjuku-ku, Tokyo 162-8640</s2>
<s3>JPN</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yamaoka, Shoji" sort="Yamaoka, Shoji" uniqKey="Yamaoka S" first="Shoji" last="Yamaoka">Shoji Yamaoka</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Molecular Virology, Graduate School of Medicine, Tokyo Medical and Dental University</s1>
<s2>Tokyo 113-8519</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tsunetsugu Yokota, Yasuko" sort="Tsunetsugu Yokota, Yasuko" uniqKey="Tsunetsugu Yokota Y" first="Yasuko" last="Tsunetsugu-Yokota">Yasuko Tsunetsugu-Yokota</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Immunology, National Institute of Infectious Diseases, Toyama 1-23-1</s1>
<s2>Shinjuku-ku, Tokyo 162-8640</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Microbes and infection</title>
<title level="j" type="abbreviated">Microbes infect.</title>
<idno type="ISSN">1286-4579</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Microbes and infection</title>
<title level="j" type="abbreviated">Microbes infect.</title>
<idno type="ISSN">1286-4579</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Immunotherapy</term>
<term>Mutation</term>
<term>Neutralization</term>
<term>Neutralizing antibody</term>
<term>Phenotype</term>
<term>Protein</term>
<term>Severe acute respiratory syndrome virus</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Virus syndrome respiratoire aigu sévère</term>
<term>Protéine</term>
<term>Neutralisation</term>
<term>Phénotype</term>
<term>Mutation</term>
<term>Anticorps neutralisant</term>
<term>Immunothérapie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In response to SARS-CoV infection, neutralizing antibodies are generated against the Spike (S) protein. Determination of the active regions that allow viral escape from neutralization would enable the use of these antibodies for future passive immunotherapy. We immunized mice with UV-inactivated SARS-CoV to generate three anti-S monoclonal antibodies, and established several neutralization escape mutants with S protein. We identified several amino acid substitutions, including Y442F and V601G in the S1 domain and D757N and A834V in the S2 region. In the presence of each neutralizing antibody, double mutants with substitutions in both domains exhibited a greater growth advantage than those with only one substitution. Importantly, combining two monoclonal antibodies that target different epitopes effected almost complete suppression of wild type virus replication. Thus, for effective passive immunotherapy, it is important to use neutralizing antibodies that recognize both the S1 and S2 regions.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1286-4579</s0>
</fA01>
<fA03 i2="1"><s0>Microbes infect.</s0>
</fA03>
<fA05><s2>10</s2>
</fA05>
<fA06><s2>8</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>A single amino acid substitution in the Sl and S2 Spike protein domains determines the neutralization escape phenotype of SARS-CoV</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MITSUKI (Yu-Ya)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>OHNISHI (Kazuo)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>TAKAGI (Hirotaka)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>OSHIMA (Masamichi)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>YAMAMOTO (Takuya)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MIZUKOSHI (Fuminori)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>TERAHARA (Kazutaka)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>KOBAYASHI (Kazuo)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>YAMAMOTO (Naoki)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>YAMAOKA (Shoji)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>TSUNETSUGU-YOKOTA (Yasuko)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Immunology, National Institute of Infectious Diseases, Toyama 1-23-1</s1>
<s2>Shinjuku-ku, Tokyo 162-8640</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Molecular Virology, Graduate School of Medicine, Tokyo Medical and Dental University</s1>
<s2>Tokyo 113-8519</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Division of Biosafety Control and Research, National Institute of Infectious Diseases</s1>
<s2>Shinjuku-ku, Tokyo 162-8640</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>AIDS Research Center, National Institute of Infectious Diseases</s1>
<s2>Shinjuku-ku, Tokyo 162-8640</s2>
<s3>JPN</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA20><s1>908-915</s1>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>26816</s2>
<s5>354000196570640090</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>28 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0451539</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Microbes and infection</s0>
</fA64>
<fA66 i1="01"><s0>FRA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>In response to SARS-CoV infection, neutralizing antibodies are generated against the Spike (S) protein. Determination of the active regions that allow viral escape from neutralization would enable the use of these antibodies for future passive immunotherapy. We immunized mice with UV-inactivated SARS-CoV to generate three anti-S monoclonal antibodies, and established several neutralization escape mutants with S protein. We identified several amino acid substitutions, including Y442F and V601G in the S1 domain and D757N and A834V in the S2 region. In the presence of each neutralizing antibody, double mutants with substitutions in both domains exhibited a greater growth advantage than those with only one substitution. Importantly, combining two monoclonal antibodies that target different epitopes effected almost complete suppression of wild type virus replication. Thus, for effective passive immunotherapy, it is important to use neutralizing antibodies that recognize both the S1 and S2 regions.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Virus syndrome respiratoire aigu sévère</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Protéine</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Protein</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Proteína</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Neutralisation</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Neutralization</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Neutralización</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Phénotype</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Phenotype</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Fenotipo</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Mutation</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Mutation</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Mutación</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Anticorps neutralisant</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Neutralizing antibody</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>anticuerpo neutralizante</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Immunothérapie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Immunotherapy</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Inmunoterapia</s0>
<s5>10</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fN21><s1>294</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
<affiliations><list><country><li>Japon</li>
</country>
<region><li>Région de Kantō</li>
</region>
<settlement><li>Tokyo</li>
</settlement>
</list>
<tree><country name="Japon"><region name="Région de Kantō"><name sortKey="Mitsuki, Yu Ya" sort="Mitsuki, Yu Ya" uniqKey="Mitsuki Y" first="Yu-Ya" last="Mitsuki">Yu-Ya Mitsuki</name>
</region>
<name sortKey="Kobayashi, Kazuo" sort="Kobayashi, Kazuo" uniqKey="Kobayashi K" first="Kazuo" last="Kobayashi">Kazuo Kobayashi</name>
<name sortKey="Mitsuki, Yu Ya" sort="Mitsuki, Yu Ya" uniqKey="Mitsuki Y" first="Yu-Ya" last="Mitsuki">Yu-Ya Mitsuki</name>
<name sortKey="Mizukoshi, Fuminori" sort="Mizukoshi, Fuminori" uniqKey="Mizukoshi F" first="Fuminori" last="Mizukoshi">Fuminori Mizukoshi</name>
<name sortKey="Ohnishi, Kazuo" sort="Ohnishi, Kazuo" uniqKey="Ohnishi K" first="Kazuo" last="Ohnishi">Kazuo Ohnishi</name>
<name sortKey="Oshima, Masamichi" sort="Oshima, Masamichi" uniqKey="Oshima M" first="Masamichi" last="Oshima">Masamichi Oshima</name>
<name sortKey="Takagi, Hirotaka" sort="Takagi, Hirotaka" uniqKey="Takagi H" first="Hirotaka" last="Takagi">Hirotaka Takagi</name>
<name sortKey="Terahara, Kazutaka" sort="Terahara, Kazutaka" uniqKey="Terahara K" first="Kazutaka" last="Terahara">Kazutaka Terahara</name>
<name sortKey="Tsunetsugu Yokota, Yasuko" sort="Tsunetsugu Yokota, Yasuko" uniqKey="Tsunetsugu Yokota Y" first="Yasuko" last="Tsunetsugu-Yokota">Yasuko Tsunetsugu-Yokota</name>
<name sortKey="Yamamoto, Naoki" sort="Yamamoto, Naoki" uniqKey="Yamamoto N" first="Naoki" last="Yamamoto">Naoki Yamamoto</name>
<name sortKey="Yamamoto, Naoki" sort="Yamamoto, Naoki" uniqKey="Yamamoto N" first="Naoki" last="Yamamoto">Naoki Yamamoto</name>
<name sortKey="Yamamoto, Takuya" sort="Yamamoto, Takuya" uniqKey="Yamamoto T" first="Takuya" last="Yamamoto">Takuya Yamamoto</name>
<name sortKey="Yamaoka, Shoji" sort="Yamaoka, Shoji" uniqKey="Yamaoka S" first="Shoji" last="Yamaoka">Shoji Yamaoka</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000299 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000299 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Checkpoint
   |type=    RBID
   |clé=     Pascal:08-0451539
   |texte=   A single amino acid substitution in the Sl and S2 Spike protein domains determines the neutralization escape phenotype of SARS-CoV
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

A single amino acid substitution in the Sl and S2 Spike protein domains determines the neutralization escape phenotype of SARS-CoV

A single amino acid substitution in the Sl and S2 Spike protein domains determines the neutralization escape phenotype of SARS-CoV

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri